UnitedHealth Group (UNH) stock has plunged more than 38% year-to-date, as the health insurer faces persistent pressure from high medical costs, especially in its Medicare Advantage (MA) business, and the ongoing Department of Justice (DOJ) investigation. The company reported better-than-expected third-quarter results and raised its full-year earnings outlook. Most Wall Street analysts remain confident about UNH’s long-term growth prospects and acknowledge the company’s efforts to streamline its business.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Moreover, Berkshire Hathaway’s (BRK.B) disclosure about buying over 5 million UnitedHealth shares, worth about $1.6 billion, reflected ace investor Warren Buffett’s confidence in the stock.
Now, according to TipRanks’ Ownership Tool, public companies and individual investors own 49.17% of UnitedHealth. They are followed by mutual funds, ETFs, other institutional investors, and insiders at 26.66%, 22.37%, 1.62%, and 0.18%, respectively.
Digging Deeper into UNH’s Ownership Structure
Looking closely at the top shareholders, Vanguard owns the highest stake in UnitedHealth at 8.50%, followed by Vanguard Index Funds with a 7.07% holding.
Among the top ETF holders, the Vanguard Total Stock Market ETF (VTI) holds a 3.15% stake in UNH, while the Vanguard S&P 500 ETF (VOO) owns 2.46%.
Moving to mutual funds, Vanguard Index Funds holds about 7.07% of UnitedHealth. Meanwhile, Fidelity Concord Street Trust owns 1.73% of the company.
Is UNH a Good Stock to Buy?
Currently, Wall Street has a Strong Buy consensus rating on UnitedHealth stock based on 17 Buys, three Holds, and one Sell recommendation. The average UNH stock price target of $395.67 indicates 27% upside potential from current levels.
